Albendazole nanocrystal and preparation method thereof

Through wet medium grinding and stabilizer combined coating technology, albendazole nanocrystals with small particle size and good stability were prepared, which solved the problem of low solubility and bioavailability of albendazole and achieved efficient Drug absorption and safe industrial production.

CN118908897APending Publication Date: 2024-11-08CHINA PHARM UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410956624.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-17
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Albendazole, as a first-line broad-spectrum antiperspirant, has problems such as poor water solubility, low solubility, poor intestinal absorption and low bioavailability, resulting in long-term medication use of large doses and prone to adverse drug reactions. The existing nanocrystal preparation method There are problems such as high process energy consumption, use of organic solvents and high amount of stabilizers.

Method used

Using wet medium grinding process, combined with a combination of charge stabilizer and space stabilizer, albendazole particles are coated through physical adsorption and hydrogen bonding to improve their solubility and bioavailability, and the average particle size is 100~ 500nm albendazole nanocrystals.

Benefits of technology

It significantly improves the solubility and bioavailability of albendazole, reduces the amount of stabilizer, is simple, safe and controllable, is suitable for large-scale industrial production, and reduces production costs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118908897A_ABST
    Figure CN118908897A_ABST
Patent Text Reader

Abstract

The invention discloses an albendazole nanocrystal and a preparation method thereof. The nanocrystal is obtained by mixing albendazole, a space stabilizer or a combined stabilizer of a charge stabilizer and the space stabilizer with water and then performing nanocrystallization treatment. The average particle size of the nanocrystal provided by the invention is 100-500nm. The solubility and the dissolution rate of the BCS II drug albendazole are improved by adopting a combined stabilizer (a charge stabilizer and a space stabilizer) or a space stabilizer through a nanocrystal technology, so that the bioavailability of the BCS II drug albendazole is improved. In addition, the preparation process is simple, efficient, safe and suitable for industrial production, and a good intermediate is provided for an albendazole preparation.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of medicines, and in particular relates to an albendazole nanocrystal and a preparation method thereof. Background Art

[0002] Albendazole, chemical name is 5-(propylthio)-2-benzimidazolecarbamic acid methyl ester, molecular formula C 12 H 15 N3O2S, molecular weight: 265.33. Albendazole is a first-line broad-spectrum anthelmintic that can effectively treat intestinal and systemic parasitic diseases. However, this drug belongs to BCS II class drugs, has poor water solubility, low solubility, poor intestinal absorption, low distribution in plasma and liver tissue, low bioavailability, and is prone to adverse drug reactions when taken in large doses for a long time. Therefore, it is necessary to take appropriate methods to improve its solubility, increase its absorption in the body, and improve its bioavailability.

[0003] Nanocrystals are a submicron colloidal dispersion system composed only of drugs and a small amount of stabilizers. They have a high drug loading capacity and a simple preparation process. Through surface modification, they can achieve targeting to the lesion site and significantly improve the solubility and bioavailability of poorly soluble drugs. They are an important strategy to increase the success rate of new drug research and development, reduce adverse reactions, and improve drug efficacy.

[0004] The preparation methods of nanocrystals are divided into top-down and bottom-up methods. The top-down method is to reduce the size of solid drug particles to the nanometer range by high-pressure homogenization or nano-grinding; the bottom-up method refers to dissolving the drug in a solvent, then precipitating it by adding an anti-solvent, and finally obtaining a nanometer powder by spraying or freeze drying. The wet ball milling method has the advantages of mature technology, simple operation, wide application range, narrow particle size distribution of the prepared nano-drugs, and no organic solvent residue. It has become the most commonly used preparation method for currently marketed nano-drugs (Malamatari M, Taylor K MG, Malamataris S, et al. Pharmaceutical nanocrystals: production by wet milling and applications [J]. Drug Discov Today, 2018, 23 (3): 534-547).

[0005] In order to improve the solubility of albendazole, researchers have successively developed and studied different preparations such as solid dispersions, inclusion compounds and liposomes. However, the above preparations have problems such as limited ability to improve the bioavailability of albendazole, excessive excipient load, and difficulty in industrialization.

[0006] At present, the research on albendazole nanocrystals mostly uses synthetic polymers such as poloxamer 188, PVP K30, and Tween 80 as stabilizers, and adopts preparation methods such as high-pressure homogenization or anti-solvent precipitation. There are problems such as high process energy consumption, use of organic solvents, and large amounts of stabilizers. Summary of the invention

[0007] Purpose of the invention: The purpose of the present invention is to provide an albendazole nanocrystal and a preparation method thereof in view of the deficiencies of the prior art. The present invention prepares albendazole nanocrystals by screening a stabilizer and optimizing a wet medium grinding process, thereby improving the bioavailability of albendazole. The preparation method of the present invention is simple to operate, easy to scale up production, and can effectively exert the antiparasitic therapeutic effect of albendazole.

[0008] Technical solution: The purpose of the present invention is achieved through the following technical solution:

[0009] The invention provides an albendazole nanocrystal. Albendazole, a stabilizer and water are mixed and then ground by wet medium to obtain an albendazole nanosuspension, namely the albendazole nanocrystal. The average particle size of the albendazole nanocrystal is 100-500nm. The stabilizer is a steric stabilizer.

[0010] The present invention also provides an albendazole nanocrystal, wherein the stabilizer is a combined stabilizer, the combined stabilizer comprises a charge stabilizer and a steric stabilizer, and the mass ratio of the charge stabilizer to the steric stabilizer is 1:9 to 9:1.

[0011] The present invention adopts a combination stabilizer and albendazole to prepare albendazole nanocrystals, fully utilizes the characteristics of the charge stabilizer, provides charge repulsion or combines with drug molecules in a hydrogen bond or other manner to weaken the aggregation of drug particles and increase the solubility of the drug; and fully utilizes the characteristics of the steric stabilizer, coats the stabilizer on the surface of albendazole particles in a physical adsorption or hydrogen bond manner, increases the steric hindrance to prevent the aggregation of drug particles, maintains the drug molecules in a supersaturated state for a certain period of time, and increases the solubility of the drug. The present invention coats the charge stabilizer and the steric stabilizer on the surface of albendazole particles in a physical adsorption or hydrogen bond manner, while preventing the aggregation of the drug, the solubility is improved. Experiments show that the solubility of albendazole nanocrystals in pH 1.0 hydrochloric acid is about 20 to 40 times higher than that of albendazole.

[0012] A preferred embodiment of the present invention is that the average particle size of the albendazole nanocrystals is 100 to 300 nm, and the zeta potential ranges from -40 to -20 mV.

[0013] Preferably, the steric stabilizer is selected from one or more of glycyrrhizic acid, diammonium glycyrrhizinate or disodium glycyrrhizinate.

[0014] Preferably, the charge stabilizer is selected from one or more of sodium glycocholate, sodium taurocholate, sodium glycodeoxycholate, sodium taurocholate, sodium cholate or sodium deoxycholate.

[0015] The natural saponin glycyrrhizic acid has liver targeting, and bile salts can promote cellular uptake mediated by the apical sodium-dependent bile salt transporter (ASBT). The albendazole nanosuspension of the present invention preferably uses glycyrrhizic acid or its salt and bile salt as a combined stabilizer, and is prepared by suspending the albendazole raw material in an aqueous solution of the combined stabilizer and grinding with a wet medium.

[0016] Further preferably, the steric stabilizer is selected from glycyrrhizic acid; the charge stabilizer is selected from sodium glycocholate; and the mass ratio of sodium glycocholate to glycyrrhizic acid is 1:1-4.

[0017] Preferably, the mass ratio of albendazole to stabilizer is 20:1 to 1:1; and the concentration of albendazole in the albendazole nanosuspension is 0.5 to 4.0%.

[0018] Further preferably, the mass ratio of albendazole to stabilizer is 8:1 to 1:1; and the concentration of albendazole in the albendazole nanosuspension is 0.5 to 2.5%.

[0019] The invention optimizes the variety, proportion, dosage and wet medium grinding process parameters of the stabilizer, thereby improving the in vitro dissolution rate and in vivo bioavailability of the poorly soluble drug albendazole.

[0020] The present invention also provides a method for preparing the albendazole nanocrystals, comprising the following steps:

[0021] (1) fully mixing the stabilizer and water to form a stabilizer solution A;

[0022] (2) adding albendazole to the stabilizer solution A obtained in step (1), stirring to suspend the drug therein, to obtain albendazole crude suspension B;

[0023] (3) subjecting the albendazole coarse suspension B obtained in step (2) to wet medium grinding to obtain an albendazole nanosuspension, i.e., the albendazole nanocrystals.

[0024] The present invention uses nano-grinding technology to process albendazole. During the grinding process, the drug and the stabilizer are co-grinded to fully prevent the aggregation of drug particles and ensure the stability of the suspension. The stability of the nano-crystals is investigated for 10 days under room temperature and low temperature conditions, and there is no obvious change in the particle size and zeta potential of the nano-crystals.

[0025] Preferably, in step (3), the process parameters of the wet medium grinding are: grinding time 2 to 8 hours, grinding speed controlled at 300 to 700 rpm, liquid-to-bead ratio 1:(2-8).

[0026] Further preferably, the process parameters of the wet medium grinding are: grinding time 3 to 7 hours, grinding speed controlled at 400 to 700 rpm, liquid-to-bead ratio 1:(2-4).

[0027] Preferably, in step (3), the particle size of the grinding beads used in the wet medium grinding is 0.2-0.5 mm, and the material is zirconia, yttrium-stabilized zirconia or stainless steel.

[0028] The invention also provides a freeze-dried solid powder of albendazole nanocrystals, which is prepared by freeze-drying the albendazole nanocrystals (ie, nanosuspension).

[0029] Preferably, the lyoprotectant used in the freeze drying is selected from any one of sucrose, lactose, fructose, mannitol, sorbitol, xylitol, polyethylene glycol 4000 or a combination thereof.

[0030] After being dried, the albendazole nanosuspension is mixed with suitable pharmaceutical excipients to form various pharmaceutically acceptable dosage forms.

[0031] The dosage form is tablet, capsule, pellet or suspension.

[0032] In the present invention, the "liquid-to-bead ratio" is the ratio of the suspension to the grinding beads used in the wet media grinding process, and the unit is "v:w".

[0033] Beneficial effects:

[0034] 1. The albendazole nanosuspension prepared by the present invention has small particle size, good stability, small amount of stabilizer and high drug loading.

[0035] 2. The albendazole nanocrystals prepared by the present invention greatly improve the solubility, dissolution and bioavailability of albendazole; provide a good intermediate for preparing other albendazole preparations, can be used to prepare various albendazole preparations, and have good application prospects.

[0036] 3. The present invention realizes a process for preparing albendazole nanosuspension by wet medium grinding. The preparation process is simple, feasible and efficient, does not use organic solvents, has low production cost, and is safe and controllable in the process. It is convenient for large-scale industrial production and is conducive to market promotion. BRIEF DESCRIPTION OF THE DRAWINGS

[0037] Figure 1 The results of the investigation on the effect of the type of charge stabilizer on the particle size of albendazole nanocrystals are shown;

[0038] Figure 2 The results of the study on the effect of the ratio of albendazole to stabilizer on the particle size of nanocrystals;

[0039] Figure 3 The results of the investigation on the effect of grinding time on the particle size of nanocrystals;

[0040] Figure 4 The results of the investigation on the effect of grinding speed on the particle size of nanocrystals;

[0041] Figure 5 The results of the investigation on the effect of liquid-to-drop ratio on the particle size of nanocrystals;

[0042] Figure 6 The short-term stability results of albendazole nanosuspension at 4°C (A, B) and room temperature (C, D);

[0043] Figure 7 The scanning electron micrographs of albendazole API (A) and nanocrystals (B);

[0044] Figure 8 Differential scanning calorimetry (DSC) curves of albendazole (a), sodium glycocholate and glycyrrhizic acid (b), albendazole and stabilizer physical mixture (c), and albendazole nanocrystals (d);

[0045] Fig. 9 is the dissolution curve of the albendazole nanocrystals of Example 1 in 0.1 mol / L hydrochloric acid solution;

[0046] Fig.10 The blood concentration-time curves of the albendazole bulk drug and nanocrystals in Example 1. DETAILED DESCRIPTION

[0047] The technical solution of the present invention is described in detail below through specific embodiments, but the protection scope of the present invention is not limited to the embodiments.

[0048] If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased through regular channels.

[0049] The experimental methods in the following examples are conventional methods unless otherwise specified. The experimental materials used in the following examples are commercially available products unless otherwise specified.

[0050] Albendazole raw material was purchased from Guangxi Yiyuan Biotechnology Co., Ltd. (purity>98%).

[0051] Example 1 Preparation of Albendazole Nanocrystals

[0052] (1) sodium glycocholate and glycyrrhizic acid are used as stabilizers in a mass ratio of 3:4, the combined stabilizer and water are fully mixed, and stirred with a magnetic stirrer to form a stabilizer solution A;

[0053] (2) adding albendazole to the stabilizer solution A obtained in step (1) at a mass ratio of albendazole raw material to combined stabilizer of 10:7, stirring to suspend the drug therein, to obtain albendazole crude suspension B;

[0054] (3) The coarse albendazole suspension B obtained in step (2) is transferred to a grinding jar of a planetary ball mill, and wet-milled with zirconium oxide grinding beads having a diameter of 0.25-0.3 mm, and shaken evenly, and the coarse suspension B and zirconium oxide grinding beads are added to the grinding jar in a ratio of 1:4 (v / w), and milled at 500 rpm for 6 h. After milling, the grinding beads are separated to obtain an albendazole nanosuspension, i.e., albendazole nanocrystals. The concentration of albendazole in the albendazole nanosuspension is 1.0%.

[0055] The average particle size of albendazole nanocrystals is 160.7±1.9nm, PDI is 0.200±0.012, and ζ potential is -32.2±0.4mV. The saturated solubility (25℃) of the API and nanosuspension in water is 0.48±0.08 and 1727.92±111.68μg / mL, respectively. The solubility of the nanosuspension is 3600 times higher than that of the API.

[0056] Example 2 Preparation of Albendazole Nanocrystals

[0057] (1) sodium glycocholate and glycyrrhizic acid are used as stabilizers in a mass ratio of 1:1, the combined stabilizer and water are fully mixed, and stirred with a magnetic stirrer to form a stabilizer solution A;

[0058] (2) adding albendazole to the stabilizer solution A obtained in step (1) at a mass ratio of albendazole API to combined stabilizer of 5:1, stirring to suspend the drug therein, to obtain albendazole crude suspension B;

[0059] (3) The coarse albendazole suspension B obtained in step (2) is transferred to a grinding jar of a planetary ball mill, and wet-milled with zirconium oxide grinding beads having a diameter of 0.25-0.3 mm, and shaken evenly, and the coarse suspension B and zirconium oxide grinding beads are added to the grinding jar in a ratio of 1:4 (v / w), and milled at 500 rpm for 6 h. After milling, the grinding beads are separated to obtain an albendazole nanosuspension, i.e., albendazole nanocrystals. The concentration of albendazole in the albendazole nanosuspension is 4.0%.

[0060] The average particle size of albendazole nanocrystals is 182.5±5.1nm, the PDI is 0.164±0.032, and the zeta potential is -31.0±0.3mV. The saturated solubility of the nanosuspension in water (25°C) is 228.43±81.28μg / mL, which is 476 times higher than that of the raw material.

[0061] Example 3 Preparation of Albendazole Nanocrystals

[0062] (1) sodium glycocholate and glycyrrhizic acid are used as stabilizers in a mass ratio of 1:1, the combined stabilizer and water are fully mixed, and stirred with a magnetic stirrer to form a stabilizer solution A;

[0063] (2) adding albendazole to the stabilizer solution A obtained in step (1) at a mass ratio of albendazole raw material to combined stabilizer of 20:1, stirring to suspend the drug therein, to obtain albendazole crude suspension B;

[0064] (3) The coarse albendazole suspension B obtained in step (2) is transferred to a grinding jar of a planetary ball mill, and wet-milled with zirconium oxide grinding beads having a diameter of 0.25-0.3 mm, and shaken evenly, and the coarse suspension B and zirconium oxide grinding beads are added to the grinding jar in a ratio of 1:4 (v / w), and milled at 500 rpm for 6 h. After milling, the grinding beads are separated to obtain an albendazole nanosuspension, i.e., albendazole nanocrystals. The concentration of albendazole in the albendazole nanosuspension is 4.0%.

[0065] The average particle size of albendazole nanocrystals is 270.3±3.1nm, the PDI is 0.284±0.023, and the zeta potential is -24.5±0.4mV. The saturated solubility of the nanosuspension in water (25°C) is 27.59±5.89μg / mL, which is 57 times higher than that of the raw material.

[0066] Example 4 Preparation of Albendazole Nanocrystals

[0067] (1) using glycyrrhizic acid as a stabilizer, fully mixing the stabilizer and water, and stirring with a magnetic stirrer to form a stabilizer solution A;

[0068] (2) adding albendazole to the stabilizer solution A obtained in step (1) at a mass ratio of albendazole raw material to stabilizer of 5:1, stirring to suspend the drug therein, to obtain albendazole crude suspension B;

[0069] (3) The coarse albendazole suspension B obtained in step (2) is transferred to a grinding jar of a planetary ball mill, and wet-milled with zirconium oxide grinding beads having a diameter of 0.25-0.3 mm, and shaken evenly, and the coarse suspension B and zirconium oxide grinding beads are added to the grinding jar in a ratio of 1:4 (v / w), and milled at 500 rpm for 6 h. After milling, the grinding beads are separated to obtain an albendazole nanosuspension, i.e., albendazole nanocrystals. The concentration of albendazole in the albendazole nanosuspension is 2.5%.

[0070] The average particle size of albendazole nanocrystals is 207.0±1.2nm, the PDI is 0.124±0.020, and the zeta potential is -23.1±1.7mV. The saturated solubility of the nanosuspension in water (25°C) is 58.13±0.16μg / mL, which is 121 times higher than that of the raw material.

[0071] Comparative Example 1

[0072] Using poloxamer 188 as a stabilizer, the mass ratio of albendazole raw material to stabilizer is 5:4, and nanocrystals are prepared according to the method and parameters of Example 4. The average particle size of albendazole nanocrystals is 371.4±4.5nm, and the PDI is 0.374±0.084. This shows that the average particle size of nanocrystals prepared with poloxamer 188 as a stabilizer is higher than that of nanocrystals prepared with glycyrrhizic acid as a stabilizer.

[0073] Example 5 Screening of Charge Stabilizer Types

[0074] 800 mg of albendazole raw material and different charge stabilizers were weighed at a mass ratio of 40:1, 20 mL of water was added, and the mixture was stirred with a magnetic stirrer to obtain a coarse suspension. The coarse suspension and 0.25-0.3 mm diameter zirconium oxide grinding beads were transferred to the grinding jar of a planetary ball mill at a ratio of 1:4 (v / w), and ground at a speed of 500 rpm for 6 h. After grinding, the grinding beads were separated to obtain an albendazole nanosuspension.

[0075] The stabilizers selected were sodium glycocholate (SGC), sodium taurocholate (STC), sodium glycodeoxycholate (SGDC) and sodium tauroglycocholate (STGC), and the particle size and polydispersity index (PDI) of each nanosuspension were measured using a particle size potentiometer.

[0076] The results are as follows Figure 1 As shown, among these four charge stabilizers, it was found that the particle size and PDI of albendazole nanosuspension stabilized with sodium glycocholate were better, and the order of particle size was: sodium glycocholate < sodium taurocholate < sodium glycodeoxycholate < sodium taurocholate.

[0077] Example 6 Screening of the ratio of each stabilizer in the combined stabilizer

[0078] The present invention refers to the preparation method of Example 1, and screens three mass ratios of sodium glycocholate to glycyrrhizic acid of 1:4, 3:4, and 4:4. The results show that the average particle sizes of albendazole nanosuspensions prepared according to the ratios of 1:4, 3:4, and 4:4 are 185.9±3.1nm, 160.7±1.9nm, and 172.1±4.6nm, respectively, and the PDIs are 0.191±0.027, 0.200±0.012, and 0.183±0.008, respectively. Among them, the particle size of the albendazole nanosuspension prepared according to the ratio of 3:4 is smaller and the stability is the best.

[0079] Example 7 Screening of the ratio of drug to combination stabilizer

[0080] The mass ratio of albendazole API to combined stabilizer was adjusted, and the other preparation methods were the same as in Example 1. Four mass ratios of albendazole API: combined stabilizer of 20:1, 20:2, 20:3, and 20:4 were screened.

[0081] The results are as follows Figure 2 As shown, it was found that the suspension prepared according to the ratio of 20:4 had a smaller particle size and better stability, with an average particle size of 178.3±3.8nm and a PDI of 0.193±0.026.

[0082] Example 8 Grinding time investigation

[0083] Zirconia beads with a diameter of 0.25-0.3 mm were selected for wet grinding, the mass ratio of sodium glycocholate to glycyrrhizic acid was 3:4, the albendazole API: stabilizer was 10:7, and the mixture was shaken evenly. The suspension and zirconium oxide grinding beads were added to the grinding jar in a ratio of 1:4 (v / w), and ground at 500 rpm for 3-7 h. The average particle size and PDI were used as evaluation indicators to investigate different grinding times.

[0084] like Figure 3 As shown, it was found that grinding for 6 hours had a better effect.

[0085] Example 9 Grinding Speed ​​Investigation

[0086] Zirconia beads with a diameter of 0.25-0.3 mm were selected for wet grinding, the mass ratio of sodium glycocholate to glycyrrhizic acid was 3:4, the albendazole API: stabilizer was 10:7, and the suspension was shaken evenly. The suspension and zirconium oxide grinding beads were added to the grinding jar in a ratio of 1:4 (v / w), and ground at 400-600 rpm for 6 h. The average particle size and PDI were used as evaluation indicators to investigate different grinding times.

[0087] like Figure 4 As shown, it was found that 500 rpm grinding effect was better.

[0088] Example 10 Liquid-to-bead ratio study

[0089] Zirconia beads with a diameter of 0.25-0.3 mm were selected for wet grinding, the mass ratio of sodium glycocholate to glycyrrhizic acid was 3:4, the albendazole bulk drug: stabilizer was 10:7, and the suspension was shaken evenly. The suspension and zirconium oxide grinding beads were added to the grinding jar in ratios of 1:2, 1:4, and 1:8 (v / w), and ground at 500 rpm for 6 h. The average particle size and PDI were used as evaluation indicators to investigate different grinding times.

[0090] like Figure 5 As shown, it was found that the grinding effect was better when the liquid-to-bead ratio was 1:4.

[0091] Example 11 Study on the stability of albendazole nanosuspension

[0092] The albendazole nanosuspension prepared in Example 1 was placed at 4°C and room temperature for 10 days. A small amount of the nanosuspension was taken at the same time period of 0, 2, 4, 6, 8, and 10 days, and the particle size, PDI, and zeta potential were measured using a Malvern laser particle size analyzer to investigate the short-term stability within 10 days. The experimental results are shown in Figure 6 .

[0093] in, Figure 6 A is the particle size and PDI results of albendazole nanosuspension at 4°C; Figure 6 B is the zeta potential result of albendazole nanosuspension at 4°C; Figure 6 C is the particle size and PDI results of albendazole nanosuspension at room temperature; Figure 6 D is the zeta potential result of albendazole nanosuspension at room temperature.

[0094] Depend on Figure 6 It can be seen that the average particle size, PDI and zeta potential of the nanosuspension on day 0 are 172.7±2.4nm, 0.184±0.049 and -30.9±0.7mV respectively. At room temperature and 4℃, the average particle size, PDI and Zeta potential of albendazole nanocrystals are stable within 10 days, and good stability can be maintained.

[0095] Example 12 Screening of Lyoprotectants

[0096] An appropriate amount of freeze-drying protective agent was added to the albendazole nanosuspension prepared in Example 1, and the mixture was evenly mixed. The mixture was transferred to a vial, pre-frozen at -80°C for 12 h, placed in a freeze dryer, and freeze-dried at a vacuum degree of 20 Pa and -50°C for 72 h to obtain a nanocrystalline solid powder.

[0097] After screening lactose, mannitol, PEG4000, and lactose-mannitol (1:1, 1:2), it was found that mannitol as a lyophilization protective agent had an ideal appearance, redispersion speed and particle size after reconstitution of the nanocrystalline lyophilized powder, so mannitol was selected as the lyophilization protective agent.

[0098] Example 13 Characterization of Albendazole Nanocrystals

[0099] (1) Scanning electron microscopy (SEM)

[0100] The morphology of the albendazole bulk drug and the nanocrystals prepared in Example 4 were analyzed using a scanning electron microscope. Figure 7 .in, Figure 7 A is the scanning electron microscope image of albendazole raw material. Figure 7 B is a scanning electron microscope image of albendazole nanocrystals. It can be observed from the image that the nanocrystals are spherical nanoparticles of uniform size, and their particle size is significantly smaller than that of the raw material drug.

[0101] (2) Differential Scanning Calorimetry (DSC)

[0102] Albendazole API, combined stabilizer (sodium glycocholate and glycyrrhizic acid), physical mixture (API and combined stabilizer) and albendazole nanocrystals of Example 1 were placed in an aluminum crucible for thermal scanning at a heating rate of 10°C / min in a temperature range of 25 to 250°C. The DSC curve is shown in FIG. Figure 8 As shown. Among them, curve a is the DSC curve of albendazole raw material, curve b is the DSC curve of combined stabilizer, curve c is the DSC curve of physical mixture, and curve d is the DSC curve of albendazole nanocrystal.

[0103] It can be seen from the figure that the API has an obvious absorption peak at around 215°C, which corresponds to the melting point of the API albendazole; the drug peak melting point of the nanocrystal is lower. According to the Van't Hoff equation, when there are trace impurities in the substance, its melting point will be lowered and the melting range will be wider. Due to the adsorption of glycyrrhizic acid and sodium glycocholate on the surface of the nanocrystal, its endothermic peak is advanced and the melting range is wider.

[0104] Example 14 In vitro dissolution study of albendazole nanocrystals

[0105] Referring to the dissolution and release determination method of the Chinese Pharmacopoeia, 900 mL of 0.1 mol / L hydrochloric acid solution (pH 1.0) was used as the dissolution medium, the paddle method was used, the rotation speed was 75 r / min, and the temperature was 37 ± 0.5 ° C. Albendazole API, albendazole nanocrystals prepared in Example 1, and a physical mixture (API and combined stabilizer) were added to each dissolution cup, and 5 mL was sampled at 5, 10, 15, 30, 45, and 60 min, respectively, filtered through a filter membrane, and 5 mL of new medium was added at the same time, and the subsequent filtrate was taken as the test solution. According to the UV-visible spectrophotometry method, the absorbance was measured at a wavelength of 308 nm, the cumulative dissolution was calculated, and the dissolution curve was drawn. The results are shown in Fig. 9 .

[0106] It can be seen from the figure that the albendazole nanocrystals prepared by the present invention have significantly improved dissolution performance compared with the raw material drug and the physical mixture.

[0107] Example 15 Pharmacokinetic Study of Albendazole Nanosuspension

[0108] 1. Animal grouping and drug administration

[0109] One hundred healthy ICR mice, male, 5 weeks old, weighing 20-30 g, were provided by Jiangsu Qinglongshan Biotechnology Co., Ltd.

[0110] Scheme: The subjects were randomly divided into two groups. The subjects were fasted for 12 hours before administration and were allowed to drink water freely. Albendazole and the albendazole nanocrystal suspension prepared in Example 1 were administered by gavage, respectively, at a dosage of 50 mg / kg.

[0111] 2. Sample collection:

[0112] At 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 h after administration, blood was collected from the eyeballs and placed in pre-heparinized EP tubes. The blood was centrifuged at 4000 rpm for 10 min at 4°C to separate the plasma, which was placed in labeled EP tubes and stored in a -80°C refrigerator.

[0113] 3. Plasma sample processing method

[0114] Take 100 μL of plasma sample, add 30 μL of 1 μg / mL tobendazole internal standard solution, vortex mix, add 600 μL of methanol, vortex thoroughly for 3 min to precipitate protein, centrifuge at 10000 r / min for 10 min, aspirate the supernatant, blow dry with nitrogen in a water bath at 45°C, redissolve the residue with 100 μL of initial mobile phase acetonitrile-0.1% acetic acid water (20:80, v / v), vortex thoroughly, centrifuge at 10000 r / min for 10 min, aspirate the supernatant, perform HPLC quantitative analysis, determine the plasma drug concentration, and draw the blood drug concentration-time curve.

[0115] 4. Data Analysis

[0116] Phoenix WinNonlin8.1.0 pharmacokinetic software was used to process the blood concentration data of albendazole metabolite albendazole sulfoxide and calculate the pharmacokinetic parameters AUC, T max , C max wait.

[0117] 5. Drug-time curve after administration

[0118] The plasma was processed and tested to obtain the drug-time curve of albendazole metabolite albendazole sulfoxide (ABZSO) at each time point (e.g. Fig.10 The peak blood concentration of ABZSO in the nanocrystal group was C max It was significantly higher than the raw material drug group, and the area under the drug-time curve (AUC) increased significantly, indicating that the oral bioavailability of the drug in the body increased significantly and the absorption of the drug increased.

[0119] 6. Pharmacokinetic parameters

[0120] After fitting with the non-compartmental model, the main pharmacokinetic parameters are shown in Table 1. The results showed that compared with the API group, the blood drug concentration of the nanocrystal group increased significantly, and the C max Increased 4.5 times; AUC of ABZSO 0→t The increase was 3.0 times, indicating that the nanocrystals effectively increased the oral bioavailability of the drug in the body.

[0121] Table 1 Comparison of pharmacokinetic results of nanocrystals and raw materials (n=5)

[0122]

[0123] As described above, although the present invention has been shown and described with reference to specific preferred embodiments, it should not be construed as limiting the present invention itself. Various changes in form and details may be made without departing from the spirit and scope of the present invention as defined in the appended claims.

Claims

1. An albendazole nanocrystal, characterized in that: Albendazole, a stabilizer and water are mixed and then ground by wet media to prepare an albendazole nanosuspension, namely the albendazole nanocrystals; the average particle size of the albendazole nanocrystals is 100-500nm; and the stabilizer is a steric stabilizer.

2. The albendazole nanocrystal according to claim 1, characterized in that: The stabilizer is a combined stabilizer, which includes a charge stabilizer and a steric stabilizer, and the mass ratio of the charge stabilizer to the steric stabilizer is 1:9 to 9:

1.

3. The albendazole nanocrystal according to claim 1 or 2, characterized in that: The average particle size of the albendazole nanocrystals is 100 to 300 nm, and the zeta potential ranges from -40 to -20 mV.

4. The albendazole nanocrystal according to claim 1 or 2, characterized in that: The steric stabilizer is selected from one or more of glycyrrhizic acid, diammonium glycyrrhizinate or disodium glycyrrhizinate.

5. The albendazole nanocrystal according to claim 2, characterized in that: The charge stabilizer is selected from one or more of sodium glycocholate, sodium taurocholate, sodium glycodeoxycholate, sodium taurocholate, sodium cholate or sodium deoxycholate.

6. The albendazole nanocrystal according to claim 4 or 5, characterized in that: The steric stabilizer is selected from glycyrrhizic acid; the charge stabilizer is selected from sodium glycocholate; the mass ratio of sodium glycocholate to glycyrrhizic acid is 1:1-4.

7. The albendazole nanocrystal according to claim 1 or 2, characterized in that: The mass ratio of the albendazole to the stabilizer is 20:1 to 1:1; and the concentration of the albendazole in the albendazole nanosuspension is 0.5 to 4.0%.

8. A method for preparing albendazole nanocrystals according to any one of claims 1 to 7, characterized in that: The following steps are involved: (1) fully mixing the stabilizer and water to form a stabilizer solution A; (2) adding albendazole to the stabilizer solution A obtained in step (1), stirring to suspend the drug therein, to obtain albendazole crude suspension B; (3) subjecting the albendazole coarse suspension B obtained in step (2) to wet medium grinding to obtain an albendazole nanosuspension, i.e., the albendazole nanocrystals.

9. The preparation method according to claim 8, characterized in that: In step (3), the process parameters of the wet medium grinding are: grinding time 2 to 8 hours, grinding speed controlled at 300 to 700 rpm, liquid-to-bead ratio 1:(2-8).

10. A freeze-dried solid powder of albendazole nanocrystal, characterized in that: The albendazole nanocrystal is prepared by freeze-drying the albendazole nanocrystal according to any one of claims 1 to 7.